ANDA 204507, held by ScieGen Pharmaceuticals. Fexofenadine Hydrochloride.
As of Nov 22, 2026, ANDA 204507 (Fexofenadine Hydrochloride Allergy, Fexofenadine Hydrochloride Hives), held by ScieGen Pharmaceuticals, was first approved by FDA on Sep 16, 2015, with 0 approved supplements and 0 published complete response letters.
Uses reduces hives and relieves itching due to hives (urticaria). This product will not prevent hives or an allergic skin reaction from occurring.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 16, 2015 | Original application | Approved | None posted |
| Fexofenadine Hydrochloride Allergy60MG ยท tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride Allergy180MG ยท tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride Hives60MG ยท tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride Hives180MG ยท tablet;oral | Fexofenadine Hydrochloride | OTC |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters